Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spero Therapeutics, Inc. (SPRO : NSDQ)

• Company Description    Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $2.76 Daily Weekly Monthly 20 Day Moving Average: 554,244 shares Shares Outstanding: 57.90 (millions) Market Capitalization: $159.81 (millions) Beta: 1.43 52 Week High: $3.22 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.43% -6.24% 12 Week 24.89% 15.45% Year To Date 18.46% 6.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 675 Massachusetts Avenue 14th Floor - Cambridge,MA 02139 USA ph: 857-242-1600 fax: - ir@sperotherapeutics.com https://sperotherapeutics.com

• General Corporate Information    Officers Esther Rajavelu - President; Chief Executive Officer; Chief Financia Milind Deshpande - Director Scott Jackson - Director John C. Pottage - Director Cynthia Smith - Director Peer Information Spero Therapeutics, Inc. (CORR.) Spero Therapeutics, Inc. (RSPI) Spero Therapeutics, Inc. (CGXP) Spero Therapeutics, Inc. (BGEN) Spero Therapeutics, Inc. (GTBP) Spero Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 84833T103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 57.90 Most Recent Split Date: (:1) Beta: 1.43 Market Capitalization: $159.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 11.50 PEG Ratio: - Price Ratios Price/Book: 3.02 Price/Cash Flow: 18.14 Price / Sales: 2.61 EPS Growth vs. Year Ago Period: 48.00% vs. Previous Quarter: -124.53% Sales Growth vs. Year Ago Period: -95.61% vs. Previous Quarter: -99.38% ROE 03/31/26 - 35.58 12/31/25 - 22.53 09/30/25 - -125.91 ROA 03/31/26 - 24.95 12/31/25 - 13.04 09/30/25 - -57.58 Current Ratio 03/31/26 - 10.50 12/31/25 - 7.59 09/30/25 - 3.83 Quick Ratio 03/31/26 - 10.50 12/31/25 - 7.59 09/30/25 - 3.83 Operating Margin 03/31/26 - 24.90 12/31/25 - 12.83 09/30/25 - -108.11 Net Margin 03/31/26 - 24.90 12/31/25 - 12.83 09/30/25 - -108.11 Pre-Tax Margin 03/31/26 - 25.33 12/31/25 - 13.22 09/30/25 - -107.39 Book Value 03/31/26 - 0.91 12/31/25 - 1.05 09/30/25 - 0.47 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©